Teva executive Mark Sabag sells 44,710 shares

Available on EDGAR 11/12/2026 - 04:12 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:12 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

TEVA Executive Vice President, International Markets Commercial Mark Sabag exercised options for 44,710 ordinary shares on November 12, 2026, at an exercise price of 34.90 per share, then sold 44,710 shares at a weighted average of $44.1410 per share. The sale prices ranged from $44.10 to $44.29. His reported option position after the exercise was zero. The options were granted February 14, 2017, and no Rule 10b5-1 plan is reported.

Insider Trade Summary

Exercise and Sale: 44,710 shares ($413K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Sabag Mark

Role See "Remarks"

Sold 44,710 shs ($1.97M)

Approx. gross sale proceeds $1.97M

Approx. exercise cost $1.56M

Approx. pre-tax spread $413K

Type	Security	Shares	Price	Value
Exercise	Stock Options (right to buy) ^F2	44,710	$0.00	$0.00
Exercise	Ordinary Shares	44,710	$34.90	$1.56M
Sale	Ordinary Shares ^F1	44,710	$44.141	$1.97M

Holdings After Transaction: Stock Options (right to buy) — 0 options (Direct); Ordinary Shares — 80,760 shares (Direct)

Footnotes (2)

F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
F2. Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

Key Figures

Options exercised: 44,710 shares Exercise price: 34.90 per share Shares sold: 44,710 shares +3 more

6 metrics

Options exercised 44,710 shares November 12, 2026

Exercise price 34.90 per share Options exercised November 12, 2026

Shares sold 44,710 shares November 12, 2026

Weighted average sale price $44.1410 per share Sale reported November 12, 2026

Sale price range $44.10–$44.29 per share Multiple transactions

Reported option position after exercise 0 options After the November 12, 2026 exercise

Key Terms

weighted average price, vested

2 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

vested financial

"30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many TEVA shares did Mark Sabag sell, and at what price?

Mark Sabag, TEVA's Executive Vice President, International Markets Commercial, sold 44,710 ordinary shares on November 12, 2026, at a weighted average price of $44.1410 per share. The shares were sold in multiple transactions at prices from $44.10 to $44.29.

What were the vesting terms for Mark Sabag's TEVA options?

The options were granted February 14, 2017; 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabag Mark

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

6944020

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See "Remarks"

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares	11/12/2026		M		44,710	A	$34.9	125,470	D
Ordinary Shares	11/12/2026		S		44,710	D	$44.141⁽¹⁾	80,760	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Options (right to buy)	$34.9	11/12/2026		M			44,710	⁽²⁾	02/14/2027	Ordinary Shares	44,710	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.10 to $44.29, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

2. Stock options were granted on February 14, 2017, with 30,236 vested on each of February 14, 2018, February 14, 2019 and February 14, 2020, and 30,238 vested on February 14, 2021.

Remarks:

Executive Vice President, International Markets Commercial

	/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR